325 (92%) af patienterne i lenalidomid/ dexamethason- gruppen fik mindst én bivirkning sammenlignet med 288 (82%) af patienterne i placebo/ dexamethason- gruppen.
325 (92%) of the patients in the lenalidomide/dexamethasone group experienced at least one adverse reaction compared to 288 (82%) in the placebo/dexamethasone group.